45% Year-Over-Year Treatment Growth Continues to Drive Adoption At Munich Center

Record Fourth Quarter Revenue Financial Highlights: Full year revenues of Euro 22.2 million, up 10% year-over-year Record fourth quarter revenue of Euro 7.0 million, up 43% year-over-year Robust 42% full year revenue attributed to Ablatherm-HIFU Ablatherm-HIFU RPP treatments increased 36% year-over-year; 40% from fourth quarter 2006 Approximately 3,400 Ablatherm-HIFU treatments worldwide for year, yielding 15,000 cumulative treatments at 176 clinical sites Successful launch of integrated Sonolith I-Sys for the disintegration of urinary stones

Dr. Andrew Weil on Ablatherm-HIFU We are proud to announce that Dr. Andrew Weil, a well-known physician and author, recently spoke of the benefits associated with Ablatherm-HIFU minimally invasive, robotized technology. Please click on the below link to view Dr.

60 Patients Successfully Treated With Sonolith I-Sys in Poland

IRBs Approve Five Additional Sites 12 Active Sites Now Screening and Enrolling Patients

EDAP Retains The Ruth Group as Investor Relations Counsel LYON, France, Jan. 24, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announced today that it has retained The Ruth Group as its investor relations

Celebrating Launch of U.S. Study and 10 Years as NASDAQ Company CEO, CFO and Medical Director Available for Media Interviews

EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer LYON, France, Dec. 13, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the release of the first multi-center

Center is First in Tennessee to Evaluate New HIFU System for Prostate Cancer

HIFU Treatments Continue High Growth FDA Trials Now Fully Funded Leading USA Hospitals in HIFU Trials